Claire Mazumdar
Chief Executive Officer at Bicara Therapeutics Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 4 years
- Director since
- 2024
4 years of board service in total across 2 boards, counting each seat separately. Longest: Bicara Therapeutics Inc., 2 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Relay Therapeutics Inc. June 9, 202683.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 10, 2026 | Bicara Therapeutics Inc. | Option exercise | +10,000 | $3.79 | $37,900 |
| Aug 10, 2026 | Bicara Therapeutics Inc. | Open-market sale | −10,000 | $27.98 | $279,800 |
| Jul 10, 2026 | Bicara Therapeutics Inc. | Option exercise | +10,000 | $3.79 | $37,900 |
| Jul 10, 2026 | Bicara Therapeutics Inc. | Open-market sale | −9,972 | $28.42 | $283,404 |
| Jul 10, 2026 | Bicara Therapeutics Inc. | Open-market sale | −28 | $29.68 | $831 |
| May 18, 2026 | Bicara Therapeutics Inc. | Option exercise | +15,000 | $3.79 | $56,850 |
| May 18, 2026 | Bicara Therapeutics Inc. | Open-market sale | −12,022 | $19.96 | $239,959 |
| May 18, 2026 | Bicara Therapeutics Inc. | Open-market sale | −2,978 | $20.35 | $60,602 |
| Apr 20, 2026 | Bicara Therapeutics Inc. | Option exercise | +15,000 | $3.79 | $56,850 |
| Apr 20, 2026 | Bicara Therapeutics Inc. | Open-market sale | −15,000 | $23.61 | $354,150 |
| Apr 16, 2026 | Bicara Therapeutics Inc. | Option exercise | +8,226 | $4.44 | $36,523 |
| Apr 16, 2026 | Bicara Therapeutics Inc. | Option exercise | +7,454 | $3.79 | $28,251 |
| Apr 16, 2026 | Bicara Therapeutics Inc. | Option exercise | +7,080 | $5.45 | $38,586 |
| Mar 20, 2026 | Bicara Therapeutics Inc. | Option exercise | +1,596 | $3.79 | $6,049 |
| Mar 20, 2026 | Bicara Therapeutics Inc. | Open-market sale | −1,596 | $18.95 | $30,244 |
Questions about Claire Mazumdar
What boards is Claire Mazumdar on?
Claire Mazumdar sits on the boards of Bicara Therapeutics Inc. and Relay Therapeutics Inc.
What company is Claire Mazumdar the CEO of?
Claire Mazumdar has been Chief Executive Officer of Bicara Therapeutics Inc. since September 2024.
How long has Claire Mazumdar served on boards?
Our records show at least 4 years of board service across 2 boards, the earliest from 2024.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.